Last week, The Multidisciplinary Association for Psychedelic Studies (MAPS) published peer-reviewed data from the second Phase III confirmatory trial of MDMA-Assisted Therapy (MDMA-AT) for PTSD in the journal Nature Medicine. From the paper’s discussion section (emphasis added):
MAPS Reaches The Last Mile: Part I
The footnote slaps.